Connect with us

Technology

Hartwig Medical Foundation and Ultima Genomics Expand Collaboration to Advance Whole-Genome Sequencing in Oncology Care

Published

on

Hartwig to adopt Ultima Genomics’ UG200 sequencing system to accelerate implementation of whole-genome-based clinical genomics workflows on Solaris 2.0 technology

Hartwig and Ultima to continue implementation and validation of ppmSeq, the only decentralizable whole-genome solution commercially available today for monitoring of minimal residual disease (MRD) with low single-digit part-per-million sensitivity

AMSTERDAM and FREMONT, Calif., June 12, 2026 /PRNewswire/ — Hartwig Medical Foundation and Ultima Genomics today announced an expansion of their strategic collaboration, marked by Hartwig’s adoption of the new Ultima UG200™, Ultima’s 2nd generation sequencing system. The agreement builds on the organization’s existing work with Ultima’s technology and is designed to accelerate Hartwig’s mission to make whole-genome sequencing (WGS) more accessible, scalable, and clinically actionable for oncology patients.

Hartwig has been a pioneer in applying WGS for cancer diagnostics. Through OncoAct Whole Genome Sequencing (OncoAct WGS), Hartwig’s comprehensive molecular diagnostic service for solid tumors analyzes the tumor genome to identify clinically relevant biomarkers, therapy options, and potential clinical trial matches. Hartwig has been working with Ultima’s first-generation sequencing system, the UG 100®, since 2024 to build deployable bioinformatics solutions and demonstrate the utility of Ultima’s new sequencing architecture for WGS in cancer testing and emerging applications such as liquid biopsy and minimal residual disease (MRD). With the addition of the UG200, Hartwig expands the scale, throughput, and breadth of its sequencing capabilities while continuing to reduce the overall cost of cancer testing and generating comprehensive genomic data across different oncology applications.

Ultima’s UG200 is powered by Ultima’s new Solaris 2.0 workflows, which provide significant advantages for deploying the UG200 into clinical laboratory settings. The simplified workflows employ an isothermal amplification process, instead of previously used emulsion-based amplification, and now integrate with standard laboratory automation and improve coverage uniformity across challenging genomic regions. The workflows reduce hands-on time, simplify operations, and are designed to support clinical-scale deployment and automation. The workflows also enable Ultima’s ultrasensitive ppmSeq technology, which provides single-digit part-per-million accuracy using WGS for applications like MRD.

“Whole-genome sequencing for oncology applications becomes transformative when it is paired with the accuracy of our flow-based chemistry and is no longer constrained by cost, capacity, or operational complexity,” said Gilad Almogy, CEO of Ultima Genomics. “Hartwig has already shown what is possible when comprehensive genomic information is connected to clinical decision-making. This next phase is about building the clinical infrastructure that enables WGS to become routine for oncology in global settings, while also opening the door to employing WGS in applications requiring deeper sequencing and extreme accuracy, such as MRD.”

A central objective of the expanded collaboration between Ultima and Hartwig is to further validate and implement Ultima’s ppmSeq technology for whole-genome-informed circulating tumor DNA (ctDNA) monitoring. Hartwig’s comprehensive tumor-genome foundation enables development of a pure WGS-based MRD approach without the operational burden of bespoke panel design, manufacturing, or patient-specific assay production.

Today, ppmSeq technology is the only broadly available, decentralized whole genome MRD workflow that can be implemented by clinical users in-house in global settings with ultra-sensitive levels of detection down to the single-digit ppm range.

This work is closely aligned with Hartwig’s clinical research direction in the Netherlands, including ongoing efforts for setting up clinical studies designed to evaluate blood-based ctDNA monitoring in patients already undergoing standard WGS-based molecular diagnostics at the Netherlands Cancer Institute (NKI). Findings from such studies are expected to help define the clinical utility, health-economic value, and implementation pathway for broader adoption of WGS-based disease monitoring in Dutch oncology care. Together, Hartwig and Ultima aim to generate evidence that supports not only technical feasibility, but also patient impact, cost-benefit assessment, and routine-care adoption.

“OncoAct WGS was built on the principle that the complete cancer genome can provide a more complete view of the patient’s disease, resulting in improved clinical actionability and more patient impact,” said Edwin Cuppen Scientific Director at Hartwig Medical Foundation. “With the UG200, we can extend that principle from therapy selection at diagnosis toward longitudinal, high-resolution disease monitoring using a one-size-fits all assay. The question is no longer whether WGS can provide value. The question is how quickly we can build the evidence, workflows, and clinical infrastructure to make that value available to more patients.”

Finally, the collaboration will also focus on building practical end-to-end workflows including extension of the Hartwig-developed comprehensive open-source cancer genomics tools (OncoAnalyser) to optimally support Ultima data and longitudinal ctDNA analysis to help the broader clinical genomics community implement Ultima technology in-house. Hartwig and Ultima intend to continue working together across laboratory automation, sample preparation, sequencing operations, data quality control, and bioinformatics.

About Hartwig Medical Foundation

Hartwig Medical Foundation is a Dutch nonprofit organization that operates globally with the mission to improve cancer patient care. They support data-driven treatment decisions through a combination of innovative software, clinical data analyses, and molecular diagnostics. This enables patients to timely receive the right treatment, while generating and making available valuable data that supports research, drug development,and the continuous improvement of care. 

About Ultima Genomics

Ultima Genomics is unleashing the power of genomics at scale. The Company’s mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology’s complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima’s revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information, and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com

Media contacts:

Ultima Genomics: Vikki Herrera, Oak Street Communications, 408-206-7009, vikki@oakstreetcommunications.com

Hartwig Medical Foundation: Edwin Cuppen, Scientific director, info@hartwigmedicalfoundation.nl, +31 20 226 9700

View original content to download multimedia:https://www.prnewswire.com/news-releases/hartwig-medical-foundation-and-ultima-genomics-expand-collaboration-to-advance-whole-genome-sequencing-in-oncology-care-302798485.html

SOURCE Ultima Genomics

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Kakunin Announces Cryptographic Compliance Shield for Google Gemini and OpenAI Agent Ecosystems

Published

on

By

SaaS Compliance Leader Launches First-Class SDK Integrations for Google Antigravity, OpenAI Swarm, and OpenAI Assistants API to Meet Strict MiCA and EU AI Act Standards.

LONDON, June 13, 2026 /PRNewswire-PRWeb/ — Kakunin, the leading compliance infrastructure platform for autonomous AI agents, today announced the release of first-class SDK integrations for Google Antigravity SDK, OpenAI Swarm, and the OpenAI Assistants API.

Autonomous agents are executing high-value, real-world tasks—but without strict boundaries, they represent a massive security risk,” said Palash Bagchi, Founder, at Kakunin.

As organizations move autonomous AI agents from sandboxes to production, securing the tools they run has become a critical operational hurdle. The new integrations allow developers to cryptographically secure and audit agent actions in real time, meeting the strict requirements of upcoming regulations like the EU AI Act and MiCA.

Preventing Agent Drift at the Tool Layer

Instead of relying on prompt engineering or system instructions—which are susceptible to jailbreaks—Kakunin secures agent tool execution at the cryptographic layer:

Pre-Flight Scope Verification: Validates that an agent possesses the required permission scope (e.g., trade.execute, file.write) before executing local code.Active-Agent Enforcement: Dynamically halts execution if the agent’s underlying X.509 certificate has been revoked or suspended.Tamper-Evident Auditing: Automatically logs session starts, prompts, responses, tool successes, and error anomalies.

Ecosystem Compatibility out of the Box

The new releases bring seamless, code-first integrations to the industry’s leading agent frameworks:

Google Antigravity SDK: Hook-based runtime protection that automatically secures Gemini-powered tool workflows.OpenAI Swarm: A lightweight class wrapper (KakuninSwarm) that dynamically gates multi-agent handoffs and task executions.OpenAI Assistants API: A polling-loop helper (handle_assistants_requires_action) that streamlines safety checks and tool output formatting in a single call.

Beyond these core OpenAI and Google environments, the new releases also extend Kakunin’s cryptographic shield to the broader agent development community. Out-of-the-box templates and shims are now available for LangChain (KakuninToolGuard), LlamaIndex (KakuninFunctionToolGuard), CrewAI (KakuninCrewAgent), and AutoGen (KakuninConversableAgent), alongside native middlewares for Next.js API routes and raw client libraries for Go, TypeScript, and Python.

“Autonomous agents are executing high-value, real-world tasks—but without strict boundaries, they represent a massive security risk,” said Palash Bagchi, Founder, at Kakunin. “By bringing cryptographic X.509 validation directly to Google’s and OpenAI’s agent loops, we are giving developers the peace of mind to deploy agents in highly regulated environments like fintech and healthcare.”

Availability

The new SDK integrations are available immediately:

Python Package: Available on PyPI via pip install kakunin.Playground Notebooks: Developers can test the integrations in 1-click via the official OpenAI Cookbook and Google Gemini Cookbook.Reference Samples: Available on the public Kakunin Samples Repository.

To learn more about securing your autonomous agent workflows, visit kakunin.ai/docs. or visit Conversational GTM for more enquiries.

Media Contact
Palash Bagchi, Immortal Reality PA LLC, 1 4125437290, ai@kakunin.ai, https://www.kakunin.ai/

View original content to download multimedia:https://www.prweb.com/releases/kakunin-announces-cryptographic-compliance-shield-for-google-gemini-and-openai-agent-ecosystems-302798798.html

SOURCE Kakunin

Continue Reading

Technology

District Taco Kicks Off The Summer’s Biggest Soccer Event with Free Delivery Offer

Published

on

By

App Users can enjoy District Taco at home with free delivery during the world’s biggest soccer tournament.

WASHINGTON, June 13, 2026 /PRNewswire-PRWeb/ — District Taco is bringing the excitement of the world’s biggest soccer tournament straight to fans’ homes with a special promotion designed to make game-day meals even more convenient.

This promotion makes it easier and more affordable to enjoy District Taco delivered right to your door so you don’t miss a moment of the action!

From June 11 through July 19, guests who order delivery through the District Taco app can use promo code ‘SOCCER26’ to receive $5 off their order, effectively offsetting the standard delivery fee and creating a free delivery experience.

Whether cheering on a favorite team, hosting a watch party, or enjoying the match from the couch, fans can enjoy District Taco’s fresh, made-to-order menu without leaving home or the extra delivery cost. “We know fans will be gathering throughout the tournament to watch some of the most exciting matches in the world,” said Osiris Hoil, CEO of District Taco. “This promotion makes it easier and more affordable to enjoy District Taco delivered right to your door so you don’t miss a moment of the action!”

The promotion is part of District Taco’s broader effort to drive digital engagement and app use. Here are the campaign details:

Enter Promo Code: ‘SOCCER26’ when placing the order in-appOffer: $5 off delivery ordersAvailable: June 11 through July 19Valid on: District Taco app delivery orders only (not third-party platforms)

Guests can download the District Taco app here for Apple users and here for Android users!

About District Taco

In 2009, two neighbors got together over some homemade chips, salsa and guacamole and decided to launch District Taco as a food cart. Since then, District Taco has opened multiple locations in Virginia, Maryland, New Jersey, New York, Pennsylvania, Florida, and Washington, DC. Their mission is to serve quality – Yucatán style – Mexican food that is fresh, simple, and healthful, with a fully customizable menu that includes vegetarian, vegan and gluten-free options. At District Taco, food is made fresh daily from the highest quality ingredients. They strive to limit their impact on the environment by serving in environmentally friendly packaging where possible. For more information about District Taco or their menu, and to download the app, visit districttaco.com or follow @districttaco across socials.

Media Contact

Raquel Robinson, District Taco, 1 5712657573, raquel.robinson@districttaco.com, districttaco.com

View original content to download multimedia:https://www.prweb.com/releases/district-taco-kicks-off-the-summers-biggest-soccer-event-with-free-delivery-offer-302799507.html

SOURCE District Taco

Continue Reading

Technology

MGI Tech Showcases Expanding Genomics Ecosystem at ESHG 2026 with New IVD Partnering Program and OEM Collaborations

Published

on

By

GOTHENBURG, Sweden, June 13, 2026 /PRNewswire/ — MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation in life sciences, is showcasing its latest advancements in sequencing, automation and clinical genomics at the European Society of Human Genetics (ESHG) 2026 Conference in Gothenburg, Sweden.

At Booth 352, MGI welcomes researchers, clinicians, laboratory leaders and industry partners to explore its comprehensive portfolio of sequencing and automation solutions while unveiling new initiatives designed to strengthen collaboration across the genomics ecosystem.

Advancing Clinical Genomics Through Partnership

A key highlight of ESHG 2026 is the launch of the MGI NGS Partner Enablement Program, a new initiative designed to connect diagnostic developers, assay providers and laboratory partners seeking to build validated clinical workflows on MGI sequencing platforms.

The program aims to accelerate the development and adoption of regulated next-generation sequencing (NGS) applications by fostering collaborations that simplify workflow implementation, reduce time-to-market and support broader access to precision medicine solutions.

“Clinical genomics is increasingly dependent on strong partnerships across the value chain,” said Fang Chen, General Manager Europe & Africa at MGI. “With the launch of our NGS Partner Enablement Program, we are creating a collaborative framework that brings together assay developers, software providers, automation partners and clinical laboratories to accelerate access to high-quality genomic testing.”

Expanding Automation Capabilities Through OEM Collaborations

At ESHG 2026, MGI is also announcing new Original Equipment Manufacturer (OEM) partnership opportunities on MGI’s DE Bundles (integrated library preparation and sequencing platform), bringing turnkey automation to global partners. The DE Bundle includes the current D4+E25 combination, as well as the new D16 paired with the E25 featuring a new 50M flow cell.

The D16, which will be launched later this year, is a benchtop, mid-to-low throughput library prep system and the upgraded successor to the D4. Retaining the fully enclosed contamination control system, it integrates a single-channel robotic pipetting module to maximize automation. With two sample preparation cartridges each processing 8 samples, the D16 delivers significantly higher throughput. The D16 and E25 systems provide flexible and scalable automation solutions for library construction, sequencing, bioinformatics analysis, streamlining the entire laboratory workflow.

Through this open OEM framework, MGI is enabling customers and solution providers to integrate proven automation technologies into customized workflows tailored to specific clinical and research applications. The OEM program reflects MGI’s commitment to building an open ecosystem that empowers laboratories to increase efficiency, improve standardization and accelerate scientific discovery.

“We are excited to expand the opportunities available to our OEM partners by providing access to the D16 platform, enabling the development of truly walkaway solutions that simplify and automate complex laboratory workflows,” said Wim Vervaeke, OEM Director at Europe & Africa at MGI. “Our innovations, including the PrepALL, E25, and G99, have already sparked new partnerships across the life sciences ecosystem. By combining MGI’s automation expertise with the specialized capabilities of our partners, we are creating integrated solutions that deliver maximum value, efficiency, and convenience for end users.”

Corporate Satellite Symposium Highlights Clinical Genomics, Precision Oncology and Spatial Multi-Omics

As part of ESHG 2026, MGI hosted its Corporate Satellite Symposium, Advancing Diagnostics: From Clinical Implementation to Biomarker Discovery, bringing together leading experts from across Europe to showcase how advanced genomic technologies are being translated into real-world clinical and research impact. The symposium highlighted applications spanning clinical oncology diagnostics, pharmacogenomics, and spatial multi-omics.

Dr. Raquel T. Lima from IPATIMUP (Portugal) presented the clinical value of RNA sequencing for detecting actionable gene fusions in solid tumours, improving diagnostic yield and supporting precision oncology decision-making. Prof. Dr. Andreas Braun from University Hospital Schleswig-Holstein (Germany) shared how spatial biology technologies map the tumour microenvironment in melanoma, revealing tumour heterogeneity, cellular interactions, and mechanisms associated with disease progression and treatment response. Dr. Andrea Conti from BMR Genomics (Italy) explored the opportunities of whole genome sequencing for pharmacogenetic marker evaluation, highlighting how comprehensive genomic approaches can support the implementation of personalised medicine through improved identification of clinically relevant variants.

Together, the presentations demonstrated how genomic and multi-omics technologies are advancing clinical diagnostics, translational oncology research, and precision medicine, while highlighting the growing role of sequencing in delivering actionable insights across healthcare and biomedical research.

Comprehensive Solutions for Genomics and Multi-Omics Research

Visitors to the MGI booth can explore the company’s comprehensive portfolio of sequencing and automation technologies supporting applications across human genetics, oncology, reproductive health, population genomics and multi-omics research.

Highlighting strong market adoption, MGI is showcasing the T7+, its ultra-high-throughput sequencing platform at the conference. Following its official launch for the Europe and Africa region at Analytica 2026 in Munich, the T7+ has gained significant momentum, with 27 units installed worldwide as of the end of 2025. From benchtop to ultra-high-throughput sequencing platforms, as well as advanced laboratory automation solutions, MGI continues to support laboratories seeking high-performance, scalable and cost-effective genomics workflows.

“Our mission extends beyond delivering innovative technologies,” said Dr. Christian Zimmerman, VP Sales Europe & Africa at MGI. “We are focused on building a complete ecosystem that enables our customers to transition seamlessly from research to clinical implementation. The partnerships and initiatives we are launching at ESHG 2026 demonstrate our commitment to making genomic technologies more accessible, integrated and impactful.”

Driving the Future of Precision Medicine in Europe

Europe remains a strategic region for MGI, with growing adoption of genomic technologies across research institutions, healthcare systems and national population initiatives.

Through continued investment in sequencing innovation, automation, clinical partnerships and collaborative ecosystem development, MGI is helping accelerate the transition toward more precise, data-driven healthcare.

As genomics increasingly becomes integrated into routine clinical practice, MGI remains committed to providing the technologies and partnerships necessary to support the next generation of precision medicine.

About MGI

MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries.

Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. As one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers, MGI empowers global users with scalable sequencing capabilities ranging from Gb to Tb levels. MGI also stands out as one of the only providers of a full-stack product portfolio that spans three core segments: SEQ ALL (short- and long-read sequencing), GLI (Generative Lab Intelligence), and Multi-Omics. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.

To learn more, please visit MGI TechLinkedInX, Instagram, and YouTube.

 

View original content:https://www.prnewswire.co.uk/news-releases/mgi-tech-showcases-expanding-genomics-ecosystem-at-eshg-2026-with-new-ivd-partnering-program-and-oem-collaborations-302799622.html

Continue Reading

Trending